Quick Answer
Decoy Therapeutics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2022.
- Decoy Therapeutics Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
- This data is from Decoy Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2023.
- XBRL data for this metric is available from 2016 to 2022 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $242.5 thousand | Q2 2017: $335.5 thousand | Q3 2017: $413.6 thousand | Q4 2017: $282.8 thousand | Q1 2018: $178.6 thousand | Q2 2018: $245.5 thousand | Q3 2018: $469.1 thousand | Q4 2018: $163.1 thousand | Q1 2019: $105.0 thousand | Q2 2019: $895.8 thousand | Q3 2019: $874.9 thousand | Q1 2020: $1.13 million | Q2 2020: $1.24 million | Q3 2020: $1.38 million | Q1 2021: $1.27 million | Q2 2021: $571.4 thousand | Q3 2021: $0.00 | Q1 2022: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00 | Q1 2023: $0.00.
- Over the full 7 years of available data (2016 to 2022), Decoy Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2022: $0.00 | Fiscal year 2021: $1.84 million | Fiscal year 2020: $5.23 million | Fiscal year 2019: $3.47 million | Fiscal year 2018: $1.95 million | Fiscal year 2017: $1.27 million | Fiscal year 2016: $1.01 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: